Results 111 to 120 of about 16,591 (206)

Artificial Intelligence and Prostate–Breast Cancer Biology: Recent Advances in Treatments and Perspectives — A Comprehensive Review

Health Science Reports, Volume 9, Issue 3, March 2026.
ABSTRACT Background and Aims The therapeutic limitations of conventional cancer treatment currently deployed are driving the development and creation of new nano‐drugs. Prostate cancer (PCa) is a prevalent clinical problem in older men with a significant global incidence, with 1.5 million cases reported in 2022.
Russell B. O. Ouma, Silas M. Ngari, Joshua K. Kibet   +2 more
wiley   +1 more source

Spongiosolysis [PDF]

, 1987
Gilbert, P., Stief, Christian Georg
core   +1 more source

Drastic Response to Olaparib in a Patient With Metastatic Castration‐Resistant Prostate Cancer Harboring BRCA2 Alterations and Near‐Threshold Tumor Mutational Burden

IJU Case Reports, Volume 9, Issue 2, March 2026.
ABSTRACT Introduction BRCA2 alterations and high tumor mutational burden (TMB‐H) are responsible for prostate cancer; however, their co‐occurrence is uncommon, and evidence for PARP inhibition in the castration‐sensitive setting remains limited. We describe a case of metastatic castration‐resistant prostate cancer (CRPC) harboring both biomarkers ...
Kotaro Yokota, Takeo Kosaka, Tatsuaki Daimon, Shinnosuke Fujiwara, Kohei Nakamura, Hiroshi Nishihara, Mototsugu Oya   +6 more
wiley   +1 more source

Targeting GRP78 and the Proteostasis Network to Break the Therapeutic Ceiling in Neuroendocrine Prostate Cancer

iNew Medicine, Volume 2, Issue 1, March 2026.
ABSTRACT HSPA5 (also known as GRP78/BiP) is a master regulator of the endoplasmic reticulum (ER) stress response and a key node in the proteostasis network. In neuroendocrine prostate cancer (NEPC), an aggressive, therapy‐refractory lineage that emerges under pressure from androgen receptor (AR) directed therapies, GRP78 is upregulated and co‐opted to ...
Amos Olalekan Akinyemi, Md Rakibul Alam, Mithu Howlader, Mohammad Esfini Farahani, Lixiang Gu, Chun Li, Chripus Ngule, Kevin Fulp, Bolaji Owoyemi, Xinyi Wang, Samuel Nwadialo, Fatemeh Selani, Makumba Esoe, Obaleye Oluwafunminiyi, Zhiguo Li   +14 more
wiley   +1 more source

A Novel Peptide, HS1002, Enhances Antitumor Activity via Dual Targeting of the GnRH Receptor and Human Telomerase Reverse Transcriptase in Prostate Cancer Cells

MedComm, Volume 7, Issue 3, March 2026.
HS1002, a new peptide targeting GnRHR and hTERT, demonstrates significant Anticancer activity in prostate cancer cells. The mechanism of HS1002 can be attributed to the reduction of serum testosterone levels by desensitization of GnRHR, the downregulation of hTERT expression and telomerase activity, and the enhancement of Anticancer immunity.
Jae Hyeon Park, Joo Chan Lee, Swati Sharma, Chunxue Jiang, Haeun Lee, Hyun‐Ju Park, Hyung Sik Kim   +6 more
wiley   +1 more source

Immune Exhaustion in Chronic Infection and Cancer: Signaling Pathways and Therapeutic Interventions

MedComm, Volume 7, Issue 3, March 2026.
Immune exhaustion is a well‐established hallmark of both cancer and chronic infection. This review proposes a novel “infection–exhaustion–tumor axis” framework, wherein chronic pathogens (e.g., oncogenic viruses) evade immune surveillance by hijacking inflammatory signaling to drive immune cell exhaustion, thereby creating immunosuppressive niches ...
Yali Song, Yazhi Mo, Si Chen, Yuemei Chen, Chunying Zhang, Shanying Deng, Juan Liao, Yi He, Wei Wang, Weidong Zheng, Tingting Zeng   +10 more
wiley   +1 more source

Companion Diagnostics in Clinical Therapy: Current Applications and Future Directions

MedComm, Volume 7, Issue 3, March 2026.
Companion diagnostics use biomarker‐based assays to stratify patients for precision therapies, improving outcomes while reducing ineffective treatment and side effects. This review summarizes the evolution, regulatory landscape, clinical applications, and technological platforms of CDx, highlighting their role in biomarker‐driven precision therapy.
Yuesong Wu, Rou Xue, Xiangwen Luo, Jiangnan Liao, Zongbo Zhang, Jinhai Deng, Teng Liu, Xin Li, Zhe‐Sheng Chen, Mingzhu Yin   +9 more
wiley   +1 more source

Clinical Application of Peripheral Blood Biomarkers for Solid Tumors

MedComm, Volume 7, Issue 3, March 2026.
Peripheral blood biomarkers provide a minimally invasive, dynamic, and potentially more accurate means to obtain a comprehensive tumor profile. Technologies for detecting them are advancing, and with the help of artificial intelligence, they are being used more and more often for cancer diagnosis, prognostic assessment, and therapeutic monitoring ...
Xinru Tu, Mengyan Tu, Junfen Xu
wiley   +1 more source

Chromatin Accessibility in Cancer: Biological Functions, Mechanisms, Therapeutic Potential, and Future Directions

MedComm, Volume 7, Issue 3, March 2026.
Cancer remains the leading cause of mortality worldwide, and drug resistance further underscores the urgent need for innovative therapeutic strategies. Chromatin, a stable yet highly dynamic nucleoprotein complex, serves as the primary carrier of genetic material in eukaryotic cells.
Wentao Xia, Min Jiang, Yefei Huang, Kun Ding, Yansu Chen   +4 more
wiley   +1 more source

Protein Lactylation in Cancer: Mechanisms and Therapeutic Targets

MedComm, Volume 7, Issue 3, March 2026.
This schematic illustrates the central role of lactylation, a lactate‐derived posttranslational modification, in linking metabolic reprogramming to cancer progression and therapy resistance. At its core, lactylation modulates proteins, influenced by metabolic shifts and environmental factors.
Qianying Ouyang, Qianyu Hu, Caiqin Wang, Yizi He, Ruolan Zeng, Yajun Li, Chang Su, Guige Lu, Xueting Zhu, Ling Xiao, Hui Zhou   +10 more
wiley   +1 more source